Drug profile · INN
trilaciclib dihydrochloride
COSELA
trilaciclib dihydrochloride (COSELA) is a cyclin-dependent kinase 4 inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — trilaciclib dihydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
trilaciclib dihydrochloride (COSELA) is a cyclin-dependent kinase 4 inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclin-dependent kinase 4 inhibitor
Primary target: Cyclin-dependent kinase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trilaciclib dihydrochloride?
trilaciclib dihydrochloride (COSELA) is a cyclin-dependent kinase 4 inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for trilaciclib dihydrochloride?
COSELA is a marketed brand name for trilaciclib dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trilaciclib dihydrochloride?
trilaciclib dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.